Madison, Wis. – DNASTAR, Inc. announced today the hiring and appointment of Tom Schwei as vice president and general manager of the Madison-based bioinformatics company. Schwei has 25 years of local business experience, including leadership and management roles, with Promega Corporation,...
Waunakee, Wis. -- Scientific Protein Laboratories, a producer of active pharmaceutical ingredients (API), was acquired by New York-based Arsenal Capital Partners....
Madison, Wis. -- Third Wave Technologies Inc, a maker of molecular diagnostic products, recently announced the release of its Invader 2D6 analysis panel, which provides clinical trial laboratories with access to a broad range of pharmacogenetic assays available for the important 2D6 gene....
CHICAGO – Early this year, the ongoing saga of the consolidating pharmaceutical industry began. For those of you who haven’t been following the news over the last two weeks, we’re talking about the “hostile” bid by French pharmaceutical giant Sanofi-Synthelabo to take over French-German pharmaceutical...
Madison, Wis.-- The world’s most common source of disease and infection is a mold called Aspergillus fumigatus. Fatal strains put transplant, leukemia and HIV/AIDS patients at serious risk. OpGen, a University of Wisconsin-Madison spinout, has created a whole genome map of this fungal pathogen that...
CHICAGO – I just returned from New York City, which was the site of the Piper Jaffray Healthcare Conference. It was held from Tuesday to Thursday last week. ...
CHICAGO – In a column last year, I commented on the growing generic pharmaceuticals business in the U.S. and around the world. Generic pharmaceuticals are not only big business but will continue to get even bigger....
Madison, Wis. -- Bruker AXS Inc., a provider of X-ray solutions for the life and materials sciences, announced Thursday that it has been selected to participate in the $22.2 million Cyttron “super microscope” project in the Netherlands. The project is half-funded by the Dutch government,...
Madison, Wis. - Sometimes the small things do count. Lucigen Corporation, which specializes in microbial enzyme cloning, has recently received $300,000 in initial investor funding. The Middleton, Wis.-based company plans to generate a total of $1 million through equity financing and a
21 January, 2004
/ 0 Comments
Though the news from last week’s H&Q conference in San Francisco is still seeping out (even though press releases were rampant, no “breaking news” made the Wall Street Journal), the overall sentiment from the meeting seems to be one of optimism. ...